Maxim Group Increases Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00

Capricor Therapeutics (NASDAQ:CAPR) had its target price boosted by analysts at Maxim Group from $12.00 to $25.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target would suggest a potential upside of 174.73% from the stock’s previous close.

A number of other brokerages have also recently commented on CAPR. Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.60.

Capricor Therapeutics Stock Performance

CAPR stock opened at $9.10 on Wednesday. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $9.24. The business’s 50-day moving average is $4.48 and its two-hundred day moving average is $5.21. The company has a market cap of $296.11 million, a price-to-earnings ratio of -10.46 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The firm had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Equities analysts predict that Capricor Therapeutics will post -1.14 earnings per share for the current year.

Insider Buying and Selling

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics during the 1st quarter valued at approximately $40,000. Main Street Financial Solutions LLC grew its holdings in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. Rhumbline Advisers purchased a new position in Capricor Therapeutics during the 2nd quarter valued at approximately $147,000. Bank of New York Mellon Corp grew its holdings in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Capricor Therapeutics during the 2nd quarter valued at approximately $426,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.